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clinical trials, it was common for glaucoma medical therapy 
to stop approximately 1 month before surgery. In my experi-
ence, cessation helps to prevent postoperative hypotony as 
well as potential choroidal effusion and hypotony maculopa-
thy due, at least in part, to the IOP-lowering effect of topical 
glaucoma medications in the early postoperative period. If 
IOP begins to rise postoperatively, it may be advisable to 
prescribe a prostaglandin analogue rather than an aqueous 
suppressant in order to maintain the aqueous lake within 
the supraciliary space. Uveoscleral outflow must be encour-
aged to ensure successful long-term outcomes with this type 
of microinvasive glaucoma surgery (MIGS). Further clinical 
study is required to confirm or contradict this hypothesis.
No. 3.  Postoperative care is comparable to that after 
cataract surgery alone. Patients are typically encouraged to 
administer prednisolone acetate 1% or difluprednate three 
to four times a day for 4 to 6 weeks postoperatively. Patients 
with more ocular inflammation than usual, perhaps related 
to retained cortex, may continue topical steroid therapy for 
a longer period of time. Loteprednol is likely a reasonable 
alternative to prednisolone acetate 1% or difluprednate. 
Many surgeons also routinely prescribe a topical nonsteroi-
dal anti-inflammatory drug to prevent postoperative pain 
and cystoid macular edema. 
CONCLUSION
Supraciliary surgical options enhance uveoscleral outflow 
and may potentially lower IOP more than trabecular bypass 
procedures, especially in patients who have a compromised 
collector system.4 With proper surgical technique and 
thoughtful perioperative care, these MIGS devices have 
promising safety and efficacy profiles for patients with mild 
to moderate open-angle glaucoma. At this time, understand-
ing of the supraciliary space, the ideal supraciliary device 
profile, and perioperative care remains in its infancy. Recent 
advances are encouraging, however, and continued progress 
will likely allow surgeons and more of their patients to avoid 
the risks of filtration blebs in the future.
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CyPass Micro-Stent
BY MARC TÖTEBERG-HARMS, MD, FEBO
Most microinvasive glaucoma surgery 
(MIGS) procedures target trabecular (con-
ventional) outflow into Schlemm canal but 
cannot completely overcome the problem 
of impaired subsequent outflow obstruc-
tion (ie, collector channels, deep venous 
plexus, and episcleral veins). The CyPass 
Micro-Stent (Alcon; Figure 1) is the first 
FDA-approved MIGS procedure that targets alternative 
uveoscleral outflow. This system is independent from tra-
becular outflow, and a negative pressure gradient between 
the anterior chamber and the supraciliary space is the 
principle behind this outflow route. The FDA approved 
the CyPass for implantation through a single clear corneal 
incision in combination with phacoemulsification cataract 
surgery plus IOL implantation. 
THE PROCEDURE
The CyPass procedure is probably one of the easiest MIGS 
procedures to learn. Because implantation of the device in 
the supraciliary space is intuitive, ophthalmologists who 
are already familiar with angle surgery should be able to 
incorporate the CyPass into their practice without much dif-
ficulty. For those unfamiliar with angle surgery, the greatest 
challenge is likely visualization of the anterior chamber angle 
with a goniolens at the microscope in the operating theater. 
Miosis is achieved with acetylcholine chloride (10 mg/mL). 
A crucial step in visualization of the anterior chamber angle 
is turning the patient’s head approximately 45º away from 
the surgeon and tilting the microscope by approximately 
This episode of Ophthalmology Insider addresses how 
new surgical devices will change the management of 
glaucoma in the future. Moderator Mark Kontos, MD, 
sits down with Kuldev Singh, MD; Steven Vold, MD; 
and Arsham Sheybani, MD.
WATCH IT NOW
bit.ly/vold0317
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the same degree in the opposite direction for a temporal 
approach. A gonioscopic lens with a Thornton ring (eg, Volk 
Transcend TVG Surgical Goniolens [Volk Optical]) can help 
the surgeon stabilize and move the eye into the desired 
direction. 
The ophthalmologist introduces the microstent sidewise 
into the anterior chamber through a corneal incision into 
the anterior chamber (filled with viscoelastic), turns the 
implant 90º to align its curvature with that of the sclera, 
and advances the device toward the opposite side of the 
eye. He or she should aim directly below the scleral spur 
(Figure 2). If the guide wire is too close to the iris, the sur-
geon will observe this tissue moving; if the guide wire is 
too far away from the iris route, he or she will encounter 
resistance during implantation. In the correct location, the 
CyPass glides into the supraciliary space with little to no 
resistance. The device should be advanced in the supracili-
ary space but not so far that none of the retention rings is 
visible in the anterior chamber (Figure 3). The number of 
rings visualized may vary, depending on the depth of the 
angle. Ideally, the proximal end of the microstent should be 
positioned between the pigmented trabecular meshwork 
and Schwalbe’s line. The guide wire is retracted, and the 
viscoelastic is washed out using irrigation and aspiration 
(see Watch It Now on p. 38). 
Patients follow a standard postcataract regimen of topical 
medication, and glaucoma medication may be discontinued 
and restarted as needed.
RESULTS
The multicenter, interventional, randomized COMPASS 
clinical trial included 2 years of follow-up.1 All patients 
had primary open-angle glaucoma and a mean diurnal 
unmedicated IOP between 21 and 33 mm Hg. After cataract 
surgery, subjects were randomized in a 1:3 ratio to either 
cataract surgery with IOL implantation alone (control group, 
n = 131) or in conjunction with CyPass implantation (mic-
rostent group, n = 374). Both groups had similar baseline 
characteristics. Sixty percent of control eyes and 77% of eyes 
that received the CyPass achieved a reduction in unmedi-
cated IOP of at least 20% at 2 years compared to baseline. 
IOP decreased by 7.4 mm Hg in the microstent group versus 
5.4 mm Hg in the control group (P < .001), and 61% of the 
microstent group and 44% of the control group had an 
unmedicated IOP between 6 and 18 mm Hg.  In addition, 
59% of the control subjects versus 85% of microstent sub-
jects were free of medication postoperatively. There were no 
vision-threatening adverse events related to the microstent, 
and more than 98% of eyes achieved 20/40 or better BCVA. 
In the microstent group, 2.9% of eyes had transient 
hypotony (IOP ≤ 5 mm Hg); all cases resolved within the first 
Figure 1.  Schematic view of the CyPass Micro-Stent. Note 
the fluid lake at the end of and around the device. 
Figure 2.  Gonioscopic view through the operating 
microscope. Approximately one-third of the microstent 
has been implanted into the supraciliary space.
Figure 3.  Gonioscopic view 1 week postoperatively. One 
retention ring is visible in the anterior chamber. The 
microstent has no contact with the endothelium, and 
no iris incarceration or contact is evident. A localized 
cyclodialisis cleft is visible directly around the device.
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2 weeks. Whereas hyphema often occurs after trabeculecto-
my (7.6% in the Tube Versus Trabeculectomy [TVT] study)2 
and with MIGS procedures that bypass the trabecular 
meshwork (eg, up to 100% after ab interno trabeculectomy 
with the Trabectome [NeoMedix]),3 this complication was 
observed in only 2.7% of eyes that received the CyPass.
1.  Vold S, Ahmed, II, Craven ER, et al. Two-year COMPASS Trial results: supraciliary microstenting with phacoemulsification 
in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123:2103-2112.
2.  Gedde SJ, Herndon LW, Brandt JD, et al; Tube Versus Trabeculectomy Study Group. Postoperative complications in the 
Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804-814.
3.  Jea SY, Francis BA, Vakili, et al. Ab interno trabeculectomy versus trabeculectomy for open-angle glaucoma. Ophthal-
mology. 2012;119(1):36-42.
Subconjunctival Space
Xen Glaucoma Treatment System
BY ERIK L. MERTENS, MD, FEBOPHTH
Microinvasive glaucoma surgery (MIGS) is 
safer and less invasive than traditional surgery 
but reduces IOP less dramatically.1,2 MIGS is 
characterized by minimal external dissection, 
a short operating time, a good safety profile, 
and patients’ rapid postoperative recovery. 
The procedures are logically classified by their 
target for aqueous outflow: Schlemm canal, 
the subconjunctival space, or the supraciliary space. The Xen 
Glaucoma Treatment System (Johnson & Johnson Vision) aims 
to lower IOP by creating a subconjunctival drainage pathway. 
THE SYSTEM
In November 2016, the FDA approved the Xen Glaucoma 
Treatment System, which consists of the Xen45 Gel Stent 
and Xen Injector. The implant is a hydrophilic tube com-
posed of a porcine gelatin cross-linked with glutaraldehyde.3 
The biocompatibility properties of gelatin are well estab-
lished and do not cause any foreign body reaction. The opti-
mal diameter of the tube is based on the laminar flow, as cal-
culated using the Hagen-Poisseuille equation, which predicts 
that flow depends on tube length, inner diameter, and flow 
viscosity. In an eye with healthy, mobile conjunctiva, not 
much outflow resistance comes from the subconjunctival 
space. To avoid a drop in IOP after surgery, all outflow resis-
tance must come from the tube itself, which is approximate-
ly 6 mm long and has an inner diameter of about 45 mm. 
Flow is 0.02 mL/sec or 1.2 mL/min (at a pressure gradient of 
5 mm Hg), thus providing approximately 6 to 8 mm Hg of 
flow resistance, which essentially eliminates hypotony.2
THE PROCEDURE
Surgery is usually performed under a sub-Tenon block, 
which achieves effective intraoperative akinesia and anal-
gesia without the possibly sight-threatening complications 
of retrobulbar injections. Typically, surgeons implant the 
stent after cataract extraction and IOL placement but before 
removing the viscoelastic, but Xen surgery can also easily be 
performed as a solo procedure. 
Ab interno glaucoma surgery requires excellent gonio-
scopic visualization for the ophthalmologist to ensure 
that the angle is open prior to delivering the implant. The 
preferred placement of the stent is in the superior-nasal 
quadrant. The surgeon measures 3 mm from the limbus and 
places two dye marks in the target area. He or she makes the 
1.8-mm main incision opposite the target area and creates 
a 1-mm sideport 60º to 90º away from the main incision. 
Marc Töteberg-Harms, MD, FEBO, demonstrates 
implantation of the CyPass Micro-Stent.
WATCH IT NOW
bit.ly/toeteberg0317
Figure 1.  The needle tip exits the sclera ±3 mm from the 
limbus before delivery of the Xen45 Gel Stent. 
